Switch theme
Sign up to access all valuation multiples
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
2022
31
Last FY Revenue $2.4M
Last FY EBITDA $0.8M
$369M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Park Ha Biological Technology achieved revenue of $2.4M and an EBITDA of $0.8M.
Park Ha Biological Technology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Park Ha Biological Technology valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $2.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 92% | XXX | XXX | XXX |
| EBITDA | XXX | $0.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 34% | XXX | XXX | XXX |
| EBIT | XXX | $0.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | 33% | XXX | XXX | XXX |
| Net Profit | XXX | $0.5M | XXX | XXX | XXX |
| Net Margin | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Park Ha Biological Technology's stock price is $14.
Park Ha Biological Technology has current market cap of $369M, and EV of $369M.
See Park Ha Biological Technology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $369M | $369M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Park Ha Biological Technology has market cap of $369M and EV of $369M.
Park Ha Biological Technology's trades at 154.7x EV/Revenue multiple, and 451.4x EV/EBITDA.
Equity research analysts estimate Park Ha Biological Technology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Park Ha Biological Technology's P/E ratio is not available.
See valuation multiples for Park Ha Biological Technology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $369M | XXX | $369M | XXX | XXX | XXX |
| EV (current) | $369M | XXX | $369M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 154.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 451.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 464.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 771.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 421.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPark Ha Biological Technology's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $45K for the same period.
Park Ha Biological Technology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Park Ha Biological Technology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Park Ha Biological Technology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $45K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Park Ha Biological Technology acquired XXX companies to date.
Last acquisition by Park Ha Biological Technology was XXXXXXXX, XXXXX XXXXX XXXXXX . Park Ha Biological Technology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Park Ha Biological Technology founded? | Park Ha Biological Technology was founded in 2022. |
| Where is Park Ha Biological Technology headquartered? | Park Ha Biological Technology is headquartered in United States of America. |
| How many employees does Park Ha Biological Technology have? | As of today, Park Ha Biological Technology has 31 employees. |
| Who is the CEO of Park Ha Biological Technology? | Park Ha Biological Technology's CEO is Ms. Xiaoqiu Zhang. |
| Is Park Ha Biological Technology publicy listed? | Yes, Park Ha Biological Technology is a public company listed on NAS. |
| What is the stock symbol of Park Ha Biological Technology? | Park Ha Biological Technology trades under PHH ticker. |
| When did Park Ha Biological Technology go public? | Park Ha Biological Technology went public in 2024. |
| Who are competitors of Park Ha Biological Technology? | Similar companies to Park Ha Biological Technology include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Park Ha Biological Technology? | Park Ha Biological Technology's current market cap is $369M |
| Is Park Ha Biological Technology profitable? | Yes, Park Ha Biological Technology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
